Leading the New Frontier of IMMUNO-REGULATION

Transforming the $10T+ inflammation economy through safe, FIRST-IN-CLASS upstream intervention.

Inflammation underlies more than 75% of modern disease. Yet today’s treatments are late, reactive, and narrow—delivering limited benefit at immense cost.

Sen-Jam is rewriting this story. Our PAIR immuno-regulator platform applies a simple but powerful therapeutic logic: address inflammation at its biological root with unmatched safety, scalability, and accessibility.

By directly modulating the immune system—rather than chasing symptoms—we are defining a new class of medicine. One that bridges prevention, longevity, and recovery. One that extends healthspan while reducing the crushing global burden of chronic disease.

Sen-Jam isn’t just improving care. We’re reframing how the world thinks about health itself—turning immuno-regulation into the foundation of the next era in healthcare.

SEE HOW PAIR WORKS
PARTNER WITH US

What We Believe

We believe unchecked inflammation is the enemy—and its first spark is our call to act.

We believe health resides upstream, not when symptoms appear.

We believe the body holds innate wisdom—and medicine should honor it.

We believe modulation is more elegant than suppression.

We believe health span is the new standard.

We don’t do sick-care. We end it.

What If We’ve Been Solving the Wrong Problem?

For decades, medicine has chased symptoms—while unchecked inflammation quietly drives disease from the inside out. Discover how one Pharmacist’s bedside insight sparked a new path forward.

A Trillion-Dollar Lever for Global Health

When you resolve inflammation at its source, you don’t just ease symptoms—you alter the course of disease itself. The ripple effect is profound: reduced suffering, extended healthspan, and a rebalanced healthcare economy.

Sen-Jam’s PAIR platform is designed to unlock this shift. Our lead assets target four of the world’s most devastating and costly health burdens—conditions that collectively drain trillions from societies and economies every year.

By moving upstream, we’re not only redefining how these diseases are treated, but also transforming the very economics of global health.

Earth 2 (2)

Metabolic Overload (overeating, obesity, alcohol-related stress)

$4.3 trillion—projected 3% of global GDP by 2035

The world’s most costly daily habit—reshaping metabolism, accelerating disease.

Saving 2 (2)

Opioid Crisis (withdrawal, dependence, tolerance)

$2.7 trillion U.S. impact in 2023 alone 

A trillion-dollar hemorrhage—where safer, inflammation-driven, non-opioid solutions are urgently needed.

Lungs 1 (2)

Respiratory Infections (COPD, URIs, COVID, RSV)

#3 global cause of death; 3.2 million COPD deaths/year  

Every breath carries a toll—where unchecked inflammation turns treatable illness into tragedy.

Electrocardiogram 1 (2)

Runaway Hospital Inflammation (Sepsis, ARDS, critical-care inflammation)

11 million deaths and $52B U.S. spend per year 

In the ICU, it’s the silent driver of cost, mortality, and system strain.

PAIR turns these towering costs into opportunity—quietly, elegantly, with a safety profile we are actively proving to be a mechanism ready to reshape global health.
Next—meet the combination duo unlocking this new frontier

Se Leather Banner Images (18)

Two Proven Molecules, One Novel Alliance

PAIR repurposes a decades-trusted NSAID and a well-characterized mast-cell modulator, tuning their ratios so they work with—rather than against—your innate immune sentinels. By soothing mast cells while dampening COX1 and COX2 in the same breath, this dynamic duo halts the inflammatory cascade upstream, turning familiar chemistry into breakthrough, tissue-sparing relief.

When one elegant alliance can be tuned like a dial, opportunity multiplies fast. Scroll on to see how the same PAIR blueprint is already branching into eleven tailored programs—some headed for the pharmacy aisle, others for the ICU—all advancing our pipeline.

Therapeutic Pipeline

Addressing Significant Unmet Needs with a Revolutionary Combination Immuno-Inflammatory Portfolio

Icon Rx  Prescription Strength Relief

Icon Otc  Over the Counter Relief

Discovery
Screening
Preclinical
Phase 1
Phase 2
Phase 3

Upper Respiratory Infections, including COVID

Obesity/MASH

SJP-002C Mild to Moderate URI infection + Treatment in Obesity/MASH - Oral
SJP-100 Critical-Care Rescue - Injectable

Metabolic Recovery (food and alcohol)

SJP-001 Metabolic Rebalance & Recovery - Oral

Opioid Use Disorder

SJP-005 Opioid Withdrawal - Oral
SJP-006 Opioid Dependence - Oral
SJP-007 Opioid Tolerance - Oral

Vaccination Side-effects

SJP-003 Adverse Effects from Vaccine - Oral

Respiratory Common Cold

SJP-002 Viral Respiratory Infection - Oral

Arthritis

SJP-004 Arthritis - Oral
SJP-101 Arthritis - Injectable

Premature Aging

SJP-200 Low-grade Chronic Inflammation - Oral

Icon Rx  Prescription Strength Relief

Icon Otc  Over the Counter Relief

COVID-19/URI
SJP-002C SARS-CoV-2-Mild to Moderate infection - Oral
PHASE 2
SJP-100 SARS-CoV-2-Severe infection - Injectable
PRECLINICAL
Adverse Effects of Alcohol
SJP-001 Alcohol Hangover Prevention - Oral
PHASE 1 END
OPIOID USE DISORDER
SJP-005 Opioid Withdrawal - Oral
PHASE 1 END
SJP-006 Opioid Dependence - Oral
Preclinical
SJP-007 Opioid Tolerance - Oral
Preclinical
VACCINATION SIDE-EFFECTS
SJP-003 Adverse Effects from Vaccine - Oral
Preclinical
UPPER RESPIRATORY INFECTIONS
SJP-002 Viral Respiratory Infection - Oral
PHASE 1
ARTHRITIS
SJP-004 Arthritis - Oral
Preclinical
SJP-101 Opioid Withdrawal - Injectable
Preclinical
Premature Aging
SJP-200 Low-grade Chronic Inflammation - Oral
Preclinical

World-Class Expertise Driving a New Standard of Care

Our leadership, scientific advisors, and collaborators draw on experience and active engagements across many of the world’s most respected institutions—helping bring Sen-Jam’s vision to the forefront of inflammation science and translational medicine.

Group 15938
Group 15939
Group 15940
Group 15941
Group 15951
Group 15952
Group 15953

Rewriting the Future of Inflammatory Care

Be part of a new chapter in medicine—where upstream solutions preserve healthspan, transform outcomes, and redefine the economics of disease.

Stay Informed
Help us change the course of global health.
2149967052 Photoroom 1 (1)

Join Our Mailing List

Media Inquiry

Leaving so soon?

Join us in revolutionizing how the world treats inflammation. Stay informed about our latest breakthroughs in pain relief, viral infections, and opioid withdrawal.

Therapeutic Pipeline

Icon Rx WhitePrescription Strength

SJP-002C Treatment for SARSCoV-2 Infection

Development: IN PHASE II CLINICAL TRIALS

We believe SJP-002C offers the world the most potent, orally available anti-inflammatory a person could obtain for a mild to moderate coronavirus infection. Since SARS-CoV-2 emerged in 2019, there’s been a frenzy of scientific research on many fronts to help us understand and deal with this virus.

While the Big Pharma giants have been touting the value of anti-virals, we believe the true culprit in regards to tackling a coronavirus infection is the runaway inflammation that results in disease progression (hospitalization) and ultimately organ damage (lung problems we so often see). Antiinflammatory drugs, including NSAIDS—non-steroidal anti-inflammatories—and antihistamines and our combination of these already proven safe agents holds the key to this kingdom. These small molecules, which have already been cleared as safe, can be very effective at calming certain, very reactive parts of the immune system while leaving other parts free to work. That means anti-inflammatories can be offered to more people with less risk than other post-exposure strategies.

International scientists agreed with our premise and wanted to partner with us in our phase II clinical trials, which we are currently engaged in. With these efforts, we are now free to explore their ability to reduce mild-to-moderate symptoms as well as the frequency of progression to severe cases. We are also interested in their ability to prevent long COVID symptoms from occurring, as we explore the relationship between long COVID and inflammation in the brain.

Therapeutic Pipeline

Icon Otc WhiteOver the Counter

SJP-001 Prevention of Veisalgia (Alcohol Hangover)

Development: Phase 1

A hangover is a group of unpleasant signs and symptoms that can develop after drinking alcohol. As if feeling awful weren’t bad enough, frequent hangovers are also associated with poor performance and conflict at work. In fact studies show that there are over a hundred billion dollars lost in productivity as a result of alcohol hangover every year in America.

As a general rule, the more alcohol you drink, the more likely you are to have a hangover the next day. But there’s no magic formula to tell you how much you can safely drink and still avoid a hangover. SJP-001 was designed to help not only treat the signs and symptoms of alcohol hangover, it actually prevents them to begin with. In human studies, SJP-001 has been shown to be effective and safe and is on the pathway to becoming the only FDA-approved agent for this ailment that has hindered societies for thousands of years.

Therapeutic Pipeline

Icon Otc WhiteOver the Counter

SJP-002 Symptoms Associated with Viral Respiratory Infections (including Coronaviruses)

Development: Preclinical

We believe SJP-002 offers the world the most potent, orally available anti-inflammatory a person could obtain OTC. Common colds and viral infections cause irritation and inflammation leading to excessive congestion, coughing, sneezing and headache. By reducing this excessive response, an individual can avoid sick days.

Coronaviruses are a family of viruses that can cause illnesses such as the common cold, severe  acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). In 2019, a  new coronavirus was identified as the cause of a disease outbreak that originated in China; known now as COVID-19.

Recalibrated to prescription strength, we believe SJP-002 could be utilized for the COVID-19 virus. We are in active clinical relationships and are extremely optimistic with early results.

Therapeutic Pipeline

OTC WhiteOver the Counter

SJP-003 Vaccine Administration

Development: Preclinical

Vaccination is the administration of a vaccine to help the immune system develop protection from a disease. Vaccines contain a microorganism or virus in a weakened, live or killed state, or proteins or toxins from the organism. In stimulating the body’s adaptive immunity, they help prevent sickness from an infectious disease.

It is well documented that any vaccine can cause side effects. For the most part these are minor (for example, a sore arm or low-grade fever) and go away within a few days. That said, however, solving for the unintended negative impact vaccinations have on people is available through the proprietary formulation found within SJP-003. When administered at the time of the vaccine shot, signs and symptoms are reduced or eliminated completely.

Therapeutic Pipeline

OTC WhiteOver the Counter

SJP-004 Arthritis

Development: Preclinical

Arthritis is an inflammation of the joints. It can affect one joint or multiple joints. There are more than 100 different types of arthritis, with different causes and treatment methods. Two of the most common types are osteoarthritis (OA) and rheumatoid arthritis (RA). The symptoms of arthritis usually develop over time, but they may also appear suddenly. Arthritis is most commonly seen in adults over the age of 65, but it can also develop in children, teens, and younger adults. Arthritis is more common in women than men and in people who are overweight.

Some of the most common symptoms involved with arthritis include swelling, joint pain and stiffness. Often range of motion will decrease as well as redness of the skin around the joint. Many people with arthritis notice their symptoms are worse in the morning. In order to solve for these painful, often debilitating symptoms, you need a pain reliever that doesn’t create additional problems down the line, like is often the case with opioid-based agents. SJP-004 is designed to help solve for the inflammation and aches involved with arthritis in a meaningfully safe manner. This helps millions of people rebound from the impact of Arthritis and experience a full strength vital lifestyle

Therapeutic Pipeline

Icon Rx WhitePrescription Strength

SJP-006 Opioid Dependence

Development: Preclinical

Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, over 2.1 million in the United States, and there are over 120,000 deaths worldwide annually attributed to opioids. There are as many patients using opioids regularly as there are patients diagnosed with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy in the United States. Opioid use disorder diagnosis is based on the American Psychiatric Association DSM-5 and includes a desire to obtain and take opioids despite social and professional consequences. Examples of opioids include heroin, morphine, codeine, fentanyl, and synthetic opioids such as oxycodone. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. Opioid use disorder includes dependence and addiction with addiction representing the most severe form of the disorder. The disease is harrowing for millions due to the physiological dependence the drug has on the person who takes it. Studies show within just a few days, someone taking opioids exhibits signs and symptoms of dependence. Mitigating dependence is one of the critical factors in turning the tides on the Opioid Epidemic. Our product has shown promising results in all three of the lock holds Opioids have on people who use them: Dependence, Tolerance and Withdrawal.

SJP-006 is designed to specifically address opioid dependence and by doing so, makes tapering off opioid pain killers a more readily available option to the millions who are prescribed opioids each year. This prevents massive destruction in terms of prolonged addiction, jeopardizing professional and personal lives and in some cases, leading to death.

Therapeutic Pipeline

Icon Rx WhitePrescription Strength

SJP-005 Opioid Withdrawal

Development: Preclinical

Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, over 2.1 million in the United States, and there are over 120,000 deaths worldwide annually attributed to opioids. There are as many patients using opioids regularly as there are patients diagnosed with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy in the United States. Opioid use disorder diagnosis is based on the American Psychiatric Association DSM-5 and includes a desire to obtain and take opioids despite social and professional consequences. Examples of opioids include heroin, morphine, codeine, fentanyl, and synthetic opioids such as oxycodone. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. Opioid use disorder includes dependence and addiction with addiction representing the most severe form of the disorder. One of the key factors that keep millions of people addicted to opioids is the fact that tapering and attempting to stop taking opioids is extremely challenging due to the harrowing impact of signs and symptoms involved with opioid withdrawal on the body. Mitigating withdrawal symptoms is one of the – if not the most important– critical factors in turning the tides on the Opioid Epidemic. Our product, SJP-005 has shown results in our pre-clinical studies to reduce signs and symptoms of withdrawal by 50%. This is a remarkable statistic, worthy of serious installation in the medical community to help combat the Opioid Crisis.

Therapeutic Pipeline

Icon Rx WhitePrescription Strength

SJP-007 Opioid Tolerance

Development: Preclinical

Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, over 2.1 million in the United States, and there are over 120,000 deaths worldwide annually attributed to opioids. There are as many patients using opioids regularly as there are patients diagnosed with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy in the United States. Opioid use disorder diagnosis is based on the American Psychiatric Association DSM-5 and includes a desire to obtain and take opioids despite social and professional consequences. Examples of opioids include heroin, morphine, codeine, fentanyl, and synthetic opioids such as oxycodone. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. Opioid use disorder includes dependence and addiction with addiction representing the most severe form of the disorder. The disease is harrowing for millions due to the physiological dependence the drug has on the person who takes it.

Opioid dependence paralyzes so many in the world is the fact that as your body physiologically becomes more and more reliant on an opioid to achieve pain relief, over time, the body requires higher doses of an opioid agent to obtain the same level of relief. This is referred to has Opioid Tolerance. We believe our product, SJP-007, helps lower individual tolerance factors to opioids, including OxyContin, morphine, oxycodone, opium, Vicodin, Demerol, hydrocodone, methadone, Suboxone, heroin, and tramadol. By lowering tolerance factors involved with opioid use disorder, more people can reverse the hold opioids have on their lives.